Effect of Beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.
The morbidity and mortality rates of patients who have had acute myocardial infarctions (AMIs) are high. Clinical guidelines recommend that most survivors of AMIs without contraindications should receive long-term treatment with beta blockade. Beta blockers have been shown to reduce mortality and reinfarction after AMI, but the pharmacologic differences among beta blockers may affect their ability to reduce these adverse events. The beta blocker carvedilol has adjunctive pharmacologic properties, including alpha(1)-blocking, antioxidant, anti-inflammatory, and antiarrhythmic activities that appear to underlie the outcomes demonstrated in experimental models and clinical trials. In conclusion, this review explores the experimental and clinical evidence supporting the preferential use of carvedilol in post-AMI patients with left ventricular dysfunction.[1]References
- Effect of Beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Kopecky, S.L. Am. J. Cardiol. (2006) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
